[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sykehuset Telemark\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":126},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,74,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100448433","genetic-study-of-amyotrophic-lateral-sclerosis-in-norway-100448433",false,"NCT05119387","Genetic Study of Amyotrophic Lateral Sclerosis in Norway","Genetisk Studie av Amyotrofisk Lateral Sklerose (ALS)","GAIN","Inclusion Criteria:\n\n* Probable or definite ALS\n* Eligible to consent\n\nExclusion Criteria:\n\n\\- not competent to give consent","ALL","16 Years","100 Years",{"count":21,"type":22},1200,"ESTIMATED","5 Years","OBSERVATIONAL","The purpose of this study is to explore the genetic causes relevant for ALS development in Norway.",[27],"Amyotrophic Lateral Sclerosis",[29,27,30,31],"Genetics","Neurology","Clinical genetics","RECRUITING","2026-05-18",{"date":35,"type":36},"2026-05-19","ACTUAL",{"date":38,"type":36},"2019-08-01",{"date":40,"type":22},"2035-12-31",{"name":42,"class":43},"Sykehuset Telemark","OTHER_GOV",17,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100605693","voices-of-transformation-a-deep-dive-into-the-struggles-and-successes-of-reclaiming-sexuality-after-sexual-trauma-100605693","NCT07165834","Voices of Transformation: A Deep Dive Into the Struggles and Successes of Reclaiming Sexuality After Sexual Trauma","Take Your Sexuality Back - a Feasibility Study of a New Intervention for Sexually Traumatized Women","Inclusion Criteria:\n\n1. A history of sexual trauma\n2. Experience trauma-related sexual problems\n3. Age between 18 and 65 years\n4. Enough competence in Norwegian to participate in a psychoeducational group.\n\nExclusion Criteria:\n\n1. Acute suicidality\n2. Serious substance abuse interfering with treatment\n3. Severe dissociative or psychotic disorders\n4. Current life crisis interfering with treatment\n5. Living in an abusive relationship. -","FEMALE","18 Years","65 Years",{"count":56,"type":22},20,"INTERVENTIONAL",[59],"NA","This study aims to gain insight into the experiences of participants in the \"Take Your Sexuality Back\" intervention groups, evaluate the intervention's acceptability, and identify necessary modifications. This study is part of a larger project that seeks to establish a scientific basis for this innovative, group-based treatment to help women who have experienced sexual trauma heal their sexuality. Before implementing the intervention in the healthcare system and initiating a larger randomized controlled trial, the investigators will evaluate the intervention's feasibility and potential efficacy, as well as gain a more comprehensive understanding of treatment outcomes. In addition to collecting quantitative data, it is crucial to gather qualitative data on participants' experiences. In this study, data will be obtained through in-depth interviews with group participants after they complete the intervention.",[62,63,64],"Sexual Abuse","Posttraumatic Stress Symptom","Sexual Trauma","2026-04-28",{"date":67,"type":36},"2026-05-04",{"date":69,"type":36},"2025-09-15",{"date":71,"type":22},"2028-12",{"name":42,"class":43},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":57,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":73},"100604310","a-feasibility-mixed-methods-study-of-the-intervention-take-your-sexuality-back-for-sexually-traumatized-women-100604310","NCT07147855","A Feasibility Mixed Methods Study of the Intervention Take Your Sexuality Back for Sexually Traumatized Women.","Take Your Sexuality Back - a Feasibility Study of a New Intervention for Sexually Traumatized Women: Preliminary Evaluations of Efficacy and Outcome Measurements","Inclusion Criteria:\n\n1. A history of sexual trauma.\n2. Experience trauma-related sexual problems.\n3. Age between 18 and 65 years.\n4. Enough competence in Norwegian to participate in a psychoeducational group.\n\nExclusion Criteria:\n\n1. Acute suicidality.\n2. Serious substance abuse interfering with treatment\n3. Severe dissociative or psychotic disorders.\n4. Current life crisis interfering with treatment.\n5. Living in an abusive relationship. -",{"count":56,"type":22},[59],"This study looks at the potential effects of a new group treatment called \"Take Your Sexuality Back\", designed for women who have experienced sexual trauma. Investigators will collect information in two ways-through forms that participants fill out themselves and through ECG measurements during a stress tests. Data will be collected before the treatment, right after it, and again three months later. When all data are collected and analyzed investigators will carry out in-depth interviews with participants and explore how they felt about being tested and how they understand the results -especially if some numbers look unusual or surprising. The goal with this study is to create a strong foundation for a future larger-scale study of the treatment by testing the methods, estimating the size of possible effects and identify outcome measurements that are experienced as meaningful to the participants.",[85,62,64],"Posttraumatic Stress Symptoms","NOT_YET_RECRUITING","2025-09-01",{"date":89,"type":36},"2025-09-08",{"date":91,"type":22},"2025-09",{"date":93,"type":22},"2027-09",{"name":42,"class":43},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":57,"phases":104,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100546697","palliative-radiotherapy-in-symptomatic-pelvic-soft-tissue-tumors-100546697","NCT06398314","Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors","PALLSOFT","Inclusion Criteria:\n\n* Patients unsuitable for curative treatment due to either advanced disease or medical contradictions (i.e comorbidity, old age, poor general condition)\n* Histologically verified primary cancer originated from gastrointestinal, urological or gynecological organs (histological verification can be performed on other lesions than the symptomatic pelvic tumor)\n* Primary, residual, recurrent or metastatic pelvic tumor from the above-mentioned cancers not amenable for curative treatment\n* Tumor-related symptoms including within the 5 defined categories pain, bleeding, bowel\u002Flower urinary\u002Fvaginal dysfunction\n* Considered candidate for palliative radiotherapy according to both study arms\n* Patient reported severity of symptoms ≥4 on a NRS- scale of 0-10\n* ≥18 years of age\n* Speaks and understands Norwegian or English\n* Ability to understand and willing to sign a written informed consent\n* ECOG performance status 0-3\n* Expected survival \\> 12 weeks\n* Able to pause systemic cancer treatment for one week prior to, during, and one week after the radiotherapy treatment\n* Women of childbearing potential (WOCBP) should have a negative highly sensitive serum pregnancy test within 72 hours prior to study intervention. WOCBP must agree to the use of highly effective birth control methods or abstain from heterosexual sexual activity from randomization and until completed study intervention\n\nExclusion Criteria:\n\n* Neuroendocrine histology of any kind\n* Sarcoma or sarcomal components in the histology\n* Tumors that originate from bony metastases without a soft tissue component\n* Unable to comply with study questionnaires\n* Ongoing treatment with an investigational drug at inclusion\n* Planned inclusion in another interventional clinical trial within 4 weeks after radiotherapy\n* Patients who are pregnant due to risk of teratogenic and abortifacient effects of radiotherapy",{"count":103,"type":22},200,[59],"PALLSOFT is a randomized, open-label, non-inferiority phase III, multicenter, national trial that will investigate whether the patient-reported symptomatic effect of palliative radiotherapy delivered in 1-2 fractions is non-inferior to palliative radiotherapy delivered in five fractions in patients with pelvic soft tissue tumors from either gastrointestinal, urological or gynecological cancer. Health-related quality of life, toxicities, survival and prognostic and predictive biomarkers will be assessed as secondary and explorative endpoints.",[107,108,109],"Gastrointestinal Cancer","Urologic Cancer","Gynecologic Cancer",[111,112,113,114,115,116],"Palliative radiotherapy","Patient-reported outcomes","Gastrointestinal cancer","Urologic cancer","Gynecologic cancer","Tumor hypoxia","2025-05-22",{"date":119,"type":36},"2025-05-23",{"date":121,"type":36},"2024-12-10",{"date":123,"type":22},"2030-12",{"name":42,"class":43},11,""]